BeyondSpring has been granted a patent for a method of treating cancer expressing mutant RAS proteins by administering Plinabulin. The treatment targets specific mutations in NRAS, HRAS, or KRAS proteins. GlobalData’s report on BeyondSpring gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on BeyondSpring, Cancer treatment biomarkers was a key innovation area identified from patents. BeyondSpring's grant share as of February 2024 was 55%. Grant share is based on the ratio of number of grants to total number of patents.
Treating cancer expressing mutant ras protein with plinabulin
A recently granted patent (Publication Number: US11918574B2) outlines a method for therapeutically treating cancer characterized by the expression of mutant forms of RAS proteins. The method involves administering Plinabulin to patients with cancers expressing mutant forms of NRAS, HRAS, or KRAS proteins, specifically those with amino acid substitutions like G12C, G12D, Q61R, Q61H, and D153V. The cancers targeted by this method include colorectal cancer, pancreatic cancer, renal cancer, lung cancer, liver cancer, breast cancer, prostate cancer, and various others, highlighting the potential broad application of this treatment approach.
Furthermore, the patent details the administration of Plinabulin in combination with other therapeutic agents such as temozolomide, bevacizumab, and cisplatin, among others, to enhance the efficacy of the treatment. The dosage range for Plinabulin administration is specified to be between 5 mg/m2 to 150 mg/m2, with various administration routes including oral, intravenous, and topical. Additionally, the method includes the option of combining Plinabulin treatment with radiation therapy to further improve outcomes. The patent also addresses specific mutant forms of NRAS and KRAS proteins and their association with cancers like multiple myeloma, endometrial cancer, colorectal cancer, renal cancer, and pancreatic cancer, offering a targeted approach for these specific cancer types.
To know more about GlobalData’s detailed insights on BeyondSpring, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
